With hundreds of drug shortages hitting the pharmaceutical industry each quarter, drugmakers are looking for novel ways to accurately forecast…More
In this week’s pharmaceutical political roundup, the Congressional Budget Office found that House Speaker Nancy Pelosi’s plan would lower government…More
Transparency in drug pricing sounds like a great idea, but a new study from the University of Southern California found fewer…More
Drug-cost watchdog Institute for Clinical and Economic Review (ICER) is out with its new draft assessment of JAK inhibitors to…More
Johnson & Johnson is facing not one but two major litigation roundups over sales of its opioids and talcum powder…More
Already behind in the PARP inhibitor race, Clovis Oncology’s Rubraca has at least won a reserved backing from England’s drug…More
The pharma industry has a reputation problem, and presidential candidates have voiced various ideas for lowering drug prices. Merck CEO…More
When generic challengers come for a branded med’s patent, drugmakers have in the past chosen to pony up and stall…More
ICER is calling out drugmakers for instituting price increases on well-known drugs that are not supported by new clinical evidence.…More
Gilead Sciences has been no stranger to controversy as consumers groups have knocked the drugmaker’s alleged profiteering with its HIV/AIDS…More
